menu
    • menu
    [{"orgOrder":0,"company":"Bionorica SE","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BX-1","moa":"11-beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bionorica SE \/ Bionorica SE","highestDevelopmentStatusID":"8","companyTruncated":"Bionorica SE \/ Bionorica SE"},{"orgOrder":0,"company":"Bionorica SE","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UKRAINE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"BNO 1030 Extract","moa":"Immune","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bionorica SE \/ Bionorica SE","highestDevelopmentStatusID":"1","companyTruncated":"Bionorica SE \/ Bionorica SE"},{"orgOrder":0,"company":"Bionorica SE","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BNO 1095","moa":"Immune","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionorica SE \/ FGK Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Bionorica SE \/ FGK Clinical Research"},{"orgOrder":0,"company":"Bionorica SE","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Bronchipret","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Bionorica SE \/ Bionorica SE","highestDevelopmentStatusID":"8","companyTruncated":"Bionorica SE \/ Bionorica SE"},{"orgOrder":0,"company":"Bionorica SE","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Chaste Berry Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionorica SE \/ Bionorica SE","highestDevelopmentStatusID":"11","companyTruncated":"Bionorica SE \/ Bionorica SE"},{"orgOrder":0,"company":"Bionorica SE","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Silimarit","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bionorica SE \/ Bionorica SE","highestDevelopmentStatusID":"9","companyTruncated":"Bionorica SE \/ Bionorica SE"}]

    Find Clinical Drug Pipeline Developments & Deals by Bionorica SE

    Menu

    Bionorica SE

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNO 1095

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

                            Details : BNO 1095 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dysmenorrhea.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 18, 2024

                            Lead Product(s) : BNO 1095

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bronchipret

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Frank Behrens

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19

                            Details : Bronchipret is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            March 11, 2022

                            Lead Product(s) : Bronchipret

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Frank Behrens

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Silimarit

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II/ Phase III

                            Recipient : Frank Behrens

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo

                            Details : Silimarit is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Chemical and Drug Induced Liver Injury.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 03, 2021

                            Lead Product(s) : Silimarit

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Frank Behrens

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNO 1030 Extract

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Undisclosed

                            Recipient : Ivano-Frankivsk National Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Imupret Application in the Technology of Delayed Prescription of Antibiotics in Patients With Acute T...

                            Details : Imupret (BNO 1030 Extract) is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Tonsillitis.

                            Product Name : Imupret

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 03, 2020

                            Lead Product(s) : BNO 1030 Extract

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Undisclosed

                            Recipient : Ivano-Frankivsk National Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chaste Berry Extract

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : Struk Tetiana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Ag...

                            Details : Chaste Berry Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 04, 2020

                            Lead Product(s) : Chaste Berry Extract

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : Struk Tetiana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Bionorica SE

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BX-1

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Charite University, Berlin, Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol

                            Details : BX-1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 26, 2020

                            Lead Product(s) : BX-1

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Charite University, Berlin, Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth